Drugs

, Volume 58, Supplement 1, pp 47–51 | Cite as

Strategies for the Management of Diabetic Dyslipidaemia

Review Article

Abstract

Atherosclerosis, the complication most prominently associated with type 2 diabetes and cardiovascular disease, represents a major burden for both individuals and society. Mortality rates associated with cardiovascular disease among patients with type 2 diabetes are at least 3 times those in the general population, and although ’traditional’ cardiovascular risk factors affect patients with this disorder as they do other individuals, they do not account for the excess risk attached to type 2 diabetes. There is a growing body of evidence to show that hyperglycaemia and dyslipidaemia are connected with this excess cardiovascular risk: hypertriglyceridaemia has been implicated in several prospective clinical studies, and available data suggest that low density lipoprotein (LDL)-cholesterol is more atherogenic in patients with type 2 diabetes than in other individuals. It is possible that this increased atherogenicity is associated with a preponderance of small, dense LDL particles that are more prone to oxidation and glycation than larger fractions and that may be involved in endothelial dysfunction. These findings lead to the recommendation of mandatory global risk assessment, accompanied by good glycaemic control, aggressive lowering of serum levels of LDL-cholesterol and maintenance of serum levels of triglyceride at the lowest possible level in patients with type 2 diabetes.

Keywords

Adis International Limited Serum Triglyceride Level Coronary Heart Disease Mortality United Kingdom Prospective Diabetes Study Good Glycaemic Control 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Pyörälä K, Laakso M, Uusitupa M. Diabetes and atherosclerosis: an epidemiological view. Diabetes Metab Rev 1987; 3: 463–524PubMedCrossRefGoogle Scholar
  2. 2.
    Stamler J, Vaccaro O, Neaton JD, et al. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care 1993; 16: 434–44PubMedCrossRefGoogle Scholar
  3. 3.
    Granger CB, Califf RM, Young S, et al. Outcome of patients with diabetes mellitus and acute myocardial infarction treated with thrombolytic agents. The Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) Study Group. J Am Coll Cardiol 1993; 21: 920–5PubMedCrossRefGoogle Scholar
  4. 4.
    Mueller HS, Cohen LS, Braunwald E, et al. Predictors of early mortality and morbidity after thrombolytic therapy of acute myocardial infarction. Analyses of patient subgroups in the Thrombolysis in Myocardial Infarction (TIMI) trial, phase II. Circulation 1992; 85: 1254–64PubMedCrossRefGoogle Scholar
  5. 5.
    Orlander PR, Goff DC, Morrissey M, et al. The relation of diabetes to the severity of acute myocardial infarction and post-myocardial infarction survival in Mexican-Americans and non-Hispanic whites. Diabetes 1994; 43: 897–902PubMedCrossRefGoogle Scholar
  6. 6.
    Stein B, Weintraub WS, Gebhart SP, et al. Influence of diabetes mellitus on early and late outcome after percutaneous transluminal coronary angioplasty. Circulation 1995; 91: 979–89PubMedCrossRefGoogle Scholar
  7. 7.
    Vigorito C, Betocchi S, Bonzani G, et al. Severity of coronary artery disease in patients with diabetes mellitus: angiographic study of 34 diabetic and 120 nondiabetic patients. Am Heart J 1980: 100 (6 Pt 1): 782–7PubMedCrossRefGoogle Scholar
  8. 8.
    Miettinen H, Lehto S, Salomaa V, et al. Impact of diabetes on mortality after the first myocardial infarction. The FINMONICA Myocardial Infarction Register Study Group. Diabetes Care 1998; 21: 69–75PubMedCrossRefGoogle Scholar
  9. 9.
    IDF Task Force on Diabetes Health Economics. Costing Diabetes: the cost of prevention. Brussels: International Diabetes Federation, 1997Google Scholar
  10. 10.
    Syvänne M, Taskinen M-R. Lipids and lipoproteins as coronary risk factors in non-insulin-dependent diabetes mellitus. Lancet 1997; 350 Suppl. 1: S120–3Google Scholar
  11. 11.
    Austin MA, Edwards KL. Small, dense low density lipoproteins, the insulin resistance syndrome and noninsulin-dependent diabetes. Curr Opin Lipidol 1996; 7: 167–71PubMedCrossRefGoogle Scholar
  12. 12.
    James RW, Pometta D. The distribution profiles of very low density and low density lipoproteins in poorly-controlled male, type 2 (non-insulin-dependent) diabetic patients. Diabetologia 1991; 34: 246–52PubMedCrossRefGoogle Scholar
  13. 13.
    Howard BJ. Lipoprotein metabolism in diabetes mellitus. J Lipid Res 1987; 28: 613–28PubMedGoogle Scholar
  14. 14.
    Taskinen M-R. Hyperlipidaemia in diabetes. Clin Endocrinol Metab 1990; 4: 743–75Google Scholar
  15. 15.
    Gibbons GF. Hyperlipidaemia of diabetes. Clin Sci 1986; 71: 477–86PubMedGoogle Scholar
  16. 16.
    Taskinen M-R. Triglyceride is the major atherogenic lipid in NIDDM. Diabetes Metab Rev 1997; 13: 93–8PubMedCrossRefGoogle Scholar
  17. 17.
    Fontbonne A, Eschwege E, Cambien F, et al. Hypertriglyceridaemia as a risk factor for coronary heart disease mortality in subjects with impaired glucose tolerance or diabetes: results from the 11-year follow-up of the Paris Prospective Study. Diabetologia 1989; 32: 300–4PubMedCrossRefGoogle Scholar
  18. 18.
    Laakso M, Lehto S, Penttilä I, et al. Lipids and lipoproteins predicting coronary heart disease mortality and morbidity in patients with non-insulin-dependent diabetes. Circulation 1993; 88: 1421–30PubMedCrossRefGoogle Scholar
  19. 19.
    Hanefeld M, Fischer S, Julius U, et al. Risk factors for myocardial infarction and death in newly detected NIDDM: the Diabetes Intervention Study, 11-year follow-up. Diabetologia 1996; 39: 1577–83PubMedCrossRefGoogle Scholar
  20. 20.
    Lehto S, Rönnemaa T, Haffner SM, et al. Dyslipidemia and hyperglycemia predict coronary heart disease events in middle-aged patients with NIDDM. Diabetes 1997; 48: 1354–9CrossRefGoogle Scholar
  21. 21.
    Turner RC, Millns H, Neil HA, et al. Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus. United Kingdom Prospective Diabetes Study (UKPDS: 23). BMJ 1998; 316: 823–8PubMedCrossRefGoogle Scholar
  22. 22.
    Taylor R, Agius L. The biochemistry of diabetes. Biochem J 1988; 250: 625–40PubMedGoogle Scholar
  23. 23.
    Brownlee M, Vlassara H, Cerami A. Non-enzymatic glycosylation and the pathogenesis of diabetic complications. Ann Intern Med 1984; 101: 527–37PubMedGoogle Scholar
  24. 24.
    De Graaf J, Hak-Lemmers HLM, Hectors MPC, et al. Enhanced susceptibility to in vitro oxidation of the dense low density lipoprotein subfraction in healthy subjects. Arterioscler Thromb 1991; 11: 298–306PubMedCrossRefGoogle Scholar
  25. 25.
    Mäkimattila S, Liu M-I, Vakkilainen J, et al. Impaired endothelium-dependent vasodilation in type 2 diabetes: relation to LDL size, oxidized LDL and antioxidants. Diabetes Care 1999; 22: 973–81PubMedCrossRefGoogle Scholar
  26. 26.
    Pyörälä K, Pedersen TR, Kjekshus J, et al. Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease. A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S). Diabetes Care 1997; 20: 614–20PubMedCrossRefGoogle Scholar
  27. 27.
    Goldberg RB, Mellies MJ, Sacks FM, et al. Cardiovascular events and their reduction with pravastatin in diabetic and glucose-intolerant myocardial infarction survivors with average cholesterol levels: subgroup analyses in the Cholesterol And Recurrent Events (CARE) Trial. Circulation 1998; 98: 2513–9PubMedCrossRefGoogle Scholar
  28. 28.
    American Diabetes Association. Management of dyslipidemia in adults with diabetes. Diabetes Care 1999; 22 Suppl. 1: 56–9CrossRefGoogle Scholar
  29. 29.
    Dunn CJ, Peters DH. Metformin: a review of its pharmacological properties and therapeutic use in non-insulin-dependent diabetes mellitus. Drugs 1995; 49: 721–49PubMedCrossRefGoogle Scholar

Copyright information

© Adis International Limited 1999

Authors and Affiliations

  1. 1.Department of MedicineUniversity of HelsinkiHelsinkiFinland

Personalised recommendations